Provides computer-aided detection and radiation therapy solutions for the early detection and treatment of cancer, focusing on improving patient outcomes.
iCAD, Inc., headquartered in Nashua, New Hampshire, specializes in advanced technology solutions aimed at enhancing cancer detection and therapy across the United States. The company operates through two primary segments: Cancer Detection and Cancer Therapy. Within its Cancer Detection segment, iCAD offers a suite of cutting-edge products including the PowerLook platform, which integrates AI-driven algorithms facilitating seamless communication between imaging systems and storage/review platforms. Its flagship product, SecondLook, employs machine learning to analyze 2D digital mammography images, identifying and highlighting suspicious masses and calcifications for further review and diagnosis. Additionally, iCAD provides automated density assessment solutions to ensure consistent and standardized evaluations.
Innovating in cancer therapy, iCAD's Cancer Therapy segment features the ProFound AI platform, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis. Complementing this, ProFound AI Risk offers breast cancer risk estimation based on mammographic screenings. Beyond breast cancer, iCAD extends its impact to detecting colonic polyps through VeraLook, supporting CT Colonography procedures. The company also contributes to oncological treatment options with its Xoft Axxent electronic brachytherapy systems, targeting early-stage breast, non-melanoma skin, and gynecological cancers. These systems are utilized across a diverse range of healthcare settings including university research hospitals, community hospitals, cancer care clinics, veterinary facilities, and dermatology offices.
Established in 1984 and originally known as Howtek, Inc., iCAD rebranded in June 2002 to reflect its focus on innovative cancer detection and therapy technologies. The company markets its products through direct sales teams, OEM partnerships, distributors, technology platforms, and resellers, catering not only to the domestic market but also exporting to Europe, Taiwan, Canada, China, and other international markets. iCAD continues to lead the charge in advancing medical technologies that empower healthcare professionals in the fight against cancer, driving forward with a commitment to enhancing patient outcomes through pioneering innovations.